




PHARMACEUTICAL 2021

Calithera Biosciences Inc.
Rank 313 of 409





PHARMACEUTICAL 2021

Calithera Biosciences Inc.
Rank 313 of 409



The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Calithera Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 228% points.

The company's Economic Capital Ratio, given in the ranking table, is -341%, being 14% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	118,703
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,401
Liabilities, Non-Current	4,815
Other Assets	6,194
Other Compr. Net Income	-39
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	690
Research and Development	71,015
Revenues	1,250
Selling, General and Administrative Expense	20,372

Output Variable	Value in 1000 USD
Assets	125,587
Liabilities	23,216
Expenses	91,387
Stockholders Equity	102,371
Net Income	-90,137
Comprehensive Net Income	-90,156
Economic Capital Ratio	-341%

